DexCom (DXCM) Stock Price, News & Analysis

Company Overview

DexCom, Inc., incorporated in 1999 and headquartered in San Diego, California, is a global leader in continuous glucose monitoring (CGM) systems for people with diabetes. The company designs, manufactures and distributes a suite of wearable devices and associated software that enable real-time glucose readings, trend analysis and personalized alerts. DexCom’s product lineup includes sensor and transmitter combinations that communicate wirelessly with receivers and compatible smart devices, providing users and their care teams with actionable insights into glucose levels throughout the day and night.

At the core of DexCom’s offerings is the FDA-approved G6 CGM system, which delivers factory-calibrated data without the need for fingersticks. Building on this platform, DexCom has introduced the G7 system—a smaller, all-in-one sensor and transmitter that offers shorter warm-up times, extended wear and enhanced connectivity. Complementing its hardware, DexCom provides DexCom Clarity, a cloud-based data management platform that aggregates glucose metrics, generates reports and supports remote monitoring through secure data sharing with healthcare professionals and family members.

DexCom operates in more than 80 countries, with direct commercial teams and distribution partnerships across North America, Europe, Asia and the Asia-Pacific region. The company works closely with payers, healthcare providers and diabetes technology partners—such as insulin pump manufacturers—to integrate CGM data into comprehensive diabetes management workflows. Its research and development efforts focus on advancing sensor accuracy, reducing device size and exploring expanded indications for CGM in both type 1 and type 2 diabetes populations.

Under the leadership of President and CEO Kevin Sayer, DexCom has grown from a start-up into a publicly traded innovator in diabetes care, committed to improving patient outcomes through continuous innovation. The executive team and board of directors bring extensive experience in medical devices, regulatory affairs and global commercialization, guiding the company’s mission to empower people to take control of their diabetes through precise, real-time glucose monitoring.

Key Stats

• Today's Range: $84.06 to $85.92
• 50-Day Range: $70.26 to $87.57
• 52-Week Range: $57.52 to $117.19
• Volume: 3.67 million shs
• Average Volume: 4.41 million shs
• Market Capitalization: $33.51 billion
• P/E Ratio: 63.78
• Dividend Yield: N/A
• Price Target: $98.50
• Consensus Rating: Moderate Buy

DexCom Stock Analysis - MarketRank™

DexCom scored higher than 97% of companies evaluated by MarketBeat, and ranked 41st out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

DexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 15 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

DexCom has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 21.18%

Earnings Growth

Earnings for DexCom are expected to grow by 21.18% in the coming year, from $2.03 to $2.46 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DexCom is 63.83, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.64.

Price to Earnings Ratio vs. Sector

The P/E ratio of DexCom is 63.83, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.18.

Price to Earnings Growth Ratio

DexCom has a PEG Ratio of 1.79. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

DexCom has a P/B Ratio of 15.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.40% of the float of DexCom has been sold short.

Short Interest Ratio / Days to Cover

DexCom has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in DexCom has recently decreased by 9.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DexCom does not currently pay a dividend.

Dividend Growth

DexCom does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.76

Percentage of Shares Shorted

2.40% of the float of DexCom has been sold short.

Short Interest Ratio / Days to Cover

DexCom has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in DexCom has recently decreased by 9.89%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 1.35

News Sentiment

DexCom has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 22 news articles for DexCom this week, compared to 26 articles on an average week.

Search Interest

Only 11 people have searched for DXCM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,281,732.00 in company stock.

Percentage Held by Insiders

Only 0.32% of the stock of DexCom is held by insiders.

Percentage Held by Institutions

97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DXCM Stock Analysis - Frequently Asked Questions

How have DXCM shares performed this year?

DexCom's stock was trading at $77.77 at the start of the year. Since then, DXCM shares have increased by 10.1% and is now trading at $85.5930.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings results on Thursday, May, 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by $0.01. DexCom's revenue for the quarter was up 12.5% compared to the same quarter last year.
Read the conference call transcript.

When did DexCom's stock split?

DexCom's stock split before market open on Friday, June 10th 2022.The 4-1 split was announced on Friday, March 25th 2022. The newly issued shares were distributed to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

Does DexCom have any subsidiaries?

The following companies are subsidiaries of DexCom: TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and more.

Who are DexCom's major shareholders?

DexCom's top institutional investors include Zevenbergen Capital Investments LLC (0.16%), Gradient Investments LLC (0.07%), Swedbank AB (0.06%) and Mn Services Vermogensbeheer B.V. (0.04%). Insiders that own company stock include Kevin R Sayer, Jacob Steven Leach, Jereme M Sylvain, Steven Robert Pacelli, Sadie Stern, Michael Jon Brown, Barry J Regan, Mark G Foletta, Steven R Altman, Paul R Flynn, Shelly Ramasamy Selvaraj, Matthew Vincent Dolan, Nicholas Augustinos and Bridgette P Heller.
View institutional ownership trends.

How do I buy shares of DexCom?

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Invesco QQQ (QQQ).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:DXCM
• CIK: 1093557
• Web: www.dexcom.com
• Phone: (858) 200-0200
• Fax: 858-200-0201
• Employees: 10,300
• Year Founded: 1999

Price Target and Rating

• Average Price Target for DexCom: $98.50
• High Price Target: $120.00
• Low Price Target: $82.00
• Potential Upside/Downside: +15.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.95
• Research Coverage: 22 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.34
• Trailing P/E Ratio: 63.78
• Forward P/E Ratio: 42.10
• P/E Growth: 1.79
• Net Income: $576.20 million
• Net Margins: 12.90%
• Pretax Margin: 17.62%
• Return on Equity: 30.05%
• Return on Assets: 10.00%

Debt

• Debt-to-Equity Ratio: 0.55
• Current Ratio: 1.50
• Quick Ratio: 1.32

Sales & Book Value

• Annual Sales: $4.03 billion
• Price / Sales: 8.31
• Cash Flow: $2.29 per share
• Price / Cash Flow: 37.27
• Book Value: $5.38 per share
• Price / Book: 15.88

Miscellaneous

• Outstanding Shares: 392,110,000
• Free Float: 390,852,000
• Market Cap: $33.51 billion
• Optionable: Optionable
• Beta: 1.44